$DMAC
DiaMedica Therapeutics Inc.

2020 Q4 Form 10-K Financial Statement

#000143774921005541 Filed on March 10, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2019 Q4 2019
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.150M $970.0K $3.690M
YoY Change 18.56% 155.26% 34.67%
% of Gross Profit
Research & Development $3.120M $1.800M $7.900M
YoY Change 73.33% 3.45% 74.7%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $21.00K
YoY Change -100.0% 40.0%
% of Gross Profit
Operating Expenses $4.270M $2.770M $11.59M
YoY Change 54.15% 30.66% 59.66%
Operating Profit -$11.59M
YoY Change 71.47%
Interest Expense $0.00 $0.00
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $80.00K $290.0K $975.0K
YoY Change -72.41% 61.11% -11.92%
Pretax Income -$4.190M -$2.480M -$10.62M
YoY Change 68.95% 26.53% 87.8%
Income Tax $10.00K $0.00 $31.00K
% Of Pretax Income
Net Earnings -$4.200M -$2.480M -$10.65M
YoY Change 69.35% 26.53% 85.72%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$223.9K -$206.5K -$888.2K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.91M $7.880M $7.880M
YoY Change 343.01% -53.15% -53.15%
Cash & Equivalents $7.409M $3.883M
Short-Term Investments $27.50M $4.000M $4.000M
Other Short-Term Assets $70.00K $140.0K $140.0K
YoY Change -50.0% -62.16% -62.16%
Inventory
Prepaid Expenses
Receivables $340.0K $823.0K
Other Receivables $0.00
Total Short-Term Assets $27.92M $8.836M $8.840M
YoY Change 215.99% -50.83% -50.81%
LONG-TERM ASSETS
Property, Plant & Equipment $74.00K $64.00K $220.0K
YoY Change 15.63% -33.33% 120.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Assets $174.0K $217.0K $210.0K
YoY Change -19.82% -40.87% -43.24%
TOTAL ASSETS
Total Short-Term Assets $27.92M $8.836M $8.840M
Total Long-Term Assets $174.0K $217.0K $210.0K
Total Assets $28.10M $9.053M $9.050M
YoY Change 210.34% -50.64% -50.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.099M $182.0K $180.0K
YoY Change 503.85% -62.32% -86.05%
Accrued Expenses $864.0K $1.076M $1.130M
YoY Change -19.7% 33.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 0.0%
Total Short-Term Liabilities $2.028M $1.318M $1.320M
YoY Change 53.87% 1.7% 1.54%
LONG-TERM LIABILITIES
Long-Term Debt $10.00K $10.00K $10.00K
YoY Change 0.0% -50.0% -50.0%
Other Long-Term Liabilities $50.00K $110.0K $110.0K
YoY Change -54.55%
Total Long-Term Liabilities $53.00K $118.0K $120.0K
YoY Change -55.08% 555.56% 500.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.028M $1.318M $1.320M
Total Long-Term Liabilities $53.00K $118.0K $120.0K
Total Liabilities $2.081M $1.436M $1.440M
YoY Change 44.92% 9.28% 9.92%
SHAREHOLDERS EQUITY
Retained Earnings -$68.91M -$56.62M
YoY Change 21.71% 23.17%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.01M $7.617M $7.620M
YoY Change
Total Liabilities & Shareholders Equity $28.10M $9.053M $9.050M
YoY Change 210.34% -50.64% -50.65%

Cashflow Statement

Concept 2020 Q4 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$4.200M -$2.480M -$10.65M
YoY Change 69.35% 26.53% 85.72%
Depreciation, Depletion And Amortization $0.00 $0.00 $21.00K
YoY Change -100.0% 40.0%
Cash From Operating Activities -$3.020M -$1.860M -$9.102M
YoY Change 62.37% -2.11% 59.8%
INVESTING ACTIVITIES
Capital Expenditures -$50.00K $0.00 $2.000K
YoY Change -100.0% -96.0%
Acquisitions
YoY Change
Other Investing Activities $710.0K $1.010M -$3.910M
YoY Change -29.7%
Cash From Investing Activities $670.0K $1.010M -$3.908M
YoY Change -33.66% 10000.0% 7716.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -30.00K 0.000 70.00K
YoY Change -100.0% -99.67%
NET CHANGE
Cash From Operating Activities -3.020M -1.860M -9.102M
Cash From Investing Activities 670.0K 1.010M -3.908M
Cash From Financing Activities -30.00K 0.000 70.00K
Net Change In Cash -2.380M -850.0K -12.94M
YoY Change 180.0% -106.57% -183.65%
FREE CASH FLOW
Cash From Operating Activities -$3.020M -$1.860M -$9.102M
Capital Expenditures -$50.00K $0.00 $2.000K
Free Cash Flow -$2.970M -$1.860M -$9.104M
YoY Change 59.68% -2.62% 58.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001401040
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18776157
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q4 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
793000
CY2020Q1 dmac Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
7700000
CY2020Q4 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
289000
CY2020 dmac Research Grant Recognized Research Activities Performed2018
ResearchGrantRecognizedResearchActivitiesPerformed2018
205000
CY2019 dmac Research Grant Recognized Research Activities Performed2018
ResearchGrantRecognizedResearchActivitiesPerformed2018
856000
CY2020Q4 dmac Working Capital
WorkingCapital
25900000
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q2 dei Entity Public Float
EntityPublicFloat
78500000
CY2020 dei Entity Registrant Name
EntityRegistrantName
DiaMedica Therapeutics Inc.
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Security12b Title
Security12bTitle
Voting common shares, no par value per share
CY2020 dei Trading Symbol
TradingSymbol
dmac
CY2020Q4 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
13000
CY2019Q4 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
433000
CY2020Q4 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
360000
CY2019Q4 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
172000
CY2020Q4 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
8000
CY2019Q4 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
52000
CY2020Q4 dmac Deferred Tax Assets Property Patents And Other
DeferredTaxAssetsPropertyPatentsAndOther
300000
CY2019Q4 dmac Deferred Tax Assets Property Patents And Other
DeferredTaxAssetsPropertyPatentsAndOther
294000
CY2020Q4 dmac Deferred Tax Assets Property Share Issue Costs
DeferredTaxAssetsPropertyShareIssueCosts
837000
CY2019Q4 dmac Deferred Tax Assets Property Share Issue Costs
DeferredTaxAssetsPropertyShareIssueCosts
395000
CY2020 dmac Effective Income Tax Rate Reconciliation Australian Research And Development Incentive
EffectiveIncomeTaxRateReconciliationAustralianResearchAndDevelopmentIncentive
-102000
CY2019 dmac Effective Income Tax Rate Reconciliation Australian Research And Development Incentive
EffectiveIncomeTaxRateReconciliationAustralianResearchAndDevelopmentIncentive
137000
CY2020 dmac Effective Income Tax Rate Reconciliation Income Tax Recovery Amount
EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount
-3274000
CY2019 dmac Effective Income Tax Rate Reconciliation Income Tax Recovery Amount
EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount
-2841000
CY2020 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
205000
CY2019 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
856000
CY2020 dmac Income Tax Rate Reconciliation Share Issuance Costs Amount
IncomeTaxRateReconciliationShareIssuanceCostsAmount
-728000
CY2019 dmac Income Tax Rate Reconciliation Share Issuance Costs Amount
IncomeTaxRateReconciliationShareIssuanceCostsAmount
CY2020 dmac Noncash Lease Expense
NoncashLeaseExpense
52000
CY2019 dmac Noncash Lease Expense
NoncashLeaseExpense
49000
CY2020Q3 dmac Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
21100000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1963000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1258000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1099000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
182000
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1099000
CY2019Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
182000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
340000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
823000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
864000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1076000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
57000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
43000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
94925000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
64232000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1843000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1164000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1701801
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2213495
CY2020Q4 us-gaap Assets
Assets
28095000
CY2019Q4 us-gaap Assets
Assets
9053000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
27921000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
8836000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
174000
CY2019Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
217000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7409000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3883000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3883000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16823000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7409000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3526000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12940000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2800899
CY2020Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2019Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2020 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2019 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18746157
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12006874
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18746157
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12006874
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
16267000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
12733000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14321000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12296000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10647000
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of credit risk</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with <div style="display: inline; font-style: italic; font: inherit;">two</div> financial institutions. These balances generally exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> experienced any losses in such accounts and believes it is <div style="display: inline; font-style: italic; font: inherit;">not</div> exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.</div></div></div></div></div></div></div></div></div></div></div></div>
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
817000
CY2019Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
817000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11211000
CY2019Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
3000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
6000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
13000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16267000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12733000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
14000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
62000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
62000
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.04
CY2020Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
10000
CY2019Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
88000
CY2020 us-gaap Depreciation
Depreciation
21000
CY2019 us-gaap Depreciation
Depreciation
21000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.89
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.27
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.27
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
483000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
419000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y146D
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1100000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4389000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3693000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-12265000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10618000
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
7000
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
13000
CY2020 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5000
CY2019 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
27000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3534000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2429000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
498000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
315000
CY2020 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
15000
CY2019 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-9000
CY2020 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
84000
CY2019 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
36000
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
26000
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2000
CY2019Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
13000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
917000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-301000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-483000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
43000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-266000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
226000
CY2020 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-78000
CY2019 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-183000
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
17000
CY2019 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-322000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
2000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
2000
CY2020 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
4000
CY2019 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
74000
CY2020Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.09
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
114000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
68000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
46000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28095000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9053000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2028000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1318000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
53000
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
118000
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
27500000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20098000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
3995000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28845000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16134000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3908000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9185000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9102000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-12292000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-10649000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
434000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
975000
CY2020 us-gaap Operating Expenses
OperatingExpenses
12699000
CY2019 us-gaap Operating Expenses
OperatingExpenses
11593000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-12699000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-11593000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
66000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
105000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
59000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
54000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
46000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
105000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
100000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
153000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
229000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
119000
CY2020Q4 us-gaap Other Receivables
OtherReceivables
49000
CY2019Q4 us-gaap Other Receivables
OtherReceivables
17000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
39746000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
12919000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
64000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
47000
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23000000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8500000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28805000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
23643000
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
9000000
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
16000
CY2019 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
13000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
45161
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
75000
CY2020 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
23000
CY2019 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
14000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
131000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
107000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
74000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
64000
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
390826
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7900000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8310000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68909000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56617000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
40697
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
4.86
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.73
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1843000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
1164000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
41000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
75000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
302332
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.73
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
998738
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1389564
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
578747
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.83
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
449556
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
5.09
CY2020 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P7Y36D
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
5.33
CY2020 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y182D
CY2020Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
5
CY2020Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4
CY2019 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1164000
CY2020 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1843000
CY2020Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4600000
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2125000
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
14283
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
28805000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
45161
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
26014000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
17025000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7617000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of estimates</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div></div></div></div></div>
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
53000
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15680320
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11987696

Files In Submission

Name View Source Status
0001437749-21-005541-index-headers.html Edgar Link pending
0001437749-21-005541-index.html Edgar Link pending
0001437749-21-005541.txt Edgar Link pending
0001437749-21-005541-xbrl.zip Edgar Link pending
dmac-20201231.xml Edgar Link completed
dmac-20201231.xsd Edgar Link pending
dmac-20201231_cal.xml Edgar Link unprocessable
dmac-20201231_def.xml Edgar Link unprocessable
dmac-20201231_lab.xml Edgar Link unprocessable
dmac-20201231_pre.xml Edgar Link unprocessable
dmtp20201231_10k.htm Edgar Link pending
ex_231575.htm Edgar Link pending
ex_231576.htm Edgar Link pending
ex_231577.htm Edgar Link pending
ex_231578.htm Edgar Link pending
ex_232726.htm Edgar Link pending
ex_232727.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kidneydisease.jpg Edgar Link pending
klk1.jpg Edgar Link pending
klk1urinaryphaseiii.jpg Edgar Link pending
neurologicaldiseases.jpg Edgar Link pending
pharmacokineticprofile.jpg Edgar Link pending
potentialbenefitsdm199.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stroketreatmentwindow.jpg Edgar Link pending
studydetails.jpg Edgar Link pending
therapeutichypothesis.jpg Edgar Link pending
therapy.jpg Edgar Link pending
urinaryalbumin.jpg Edgar Link pending